title: Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy.
abstract: OBJECTIVE
  This study was undertaken to evaluate mid-term clinical results of non-surgical myocardial reduction in patients with hypertrophic obstructive cardiomyopathy.
  
  
  METHODS
  Twenty-five patients with left ventricular outflow tract obstruction (mean gradient of 84. 54+/-31.38 mmHg) and symptoms of dyspnoea, angina and/or syncope were treated with non-surgical myocardial reduction. The patients were followed-up for a mean period of 10.44+/-1.8 months. In all patients clinical examination with echocardiography was repeated after every 3 months of follow-up, and a symptom-limited treadmill test was repeated at the 6 month follow-up. Eighteen patients underwent simultaneous respiratory gas analysis.
  
  
  RESULTS
  Clinical follow-up examinations were achieved in all 25 patients. Persistent left ventricular outflow tract gradient reduction was seen in 23 patients. Seventeen patients had a reduction of left ventricular outflow tract gradient >50% of baseline value. Twenty patients showed a clinical improvement from 2.8+/-0.5 up to 1.2+/-0.5 NYHA class (P<0.001). The clinical improvement was matched by an improvement in objective measures of exercise capacity in patients with significant left ventricular outflow tract gradient reduction. Exercise time increased from 571.9+/-192.2 to 703.5+/-175.4 s, P<0. 001, and peak VO(2)increased from 14.6+/-5.2 to 20.5+/-8.6 ml. kg(-1)min(-1), P<0.05.
  
  
  CONCLUSIONS
  Significant left ventricular outflow tract gradient reduction with exercise capacity improvement was achieved in the majority of patients treated with non-surgical myocardial reduction. We recommend this method as an alternative to surgery for symptomatic patients with hypertrophic obstructive cardiomyopathy.
authors.affiliation: National Institute of Cardiology, Warsaw, Poland.
authors.forename: W
authors.initials: W
authors.lastname: Ruzyłło
authors.forename: L
authors.initials: L
authors.lastname: Chojnowska
authors.forename: M
authors.initials: M
authors.lastname: Demkow
authors.forename: A
authors.initials: A
authors.lastname: Witkowski
authors.forename: B
authors.initials: B
authors.lastname: Kuśmierczyk-Droszcz
authors.forename: W
authors.initials: W
authors.lastname: Piotrowski
authors.forename: L
authors.initials: L
authors.lastname: Rausinska
authors.forename: M
authors.initials: M
authors.lastname: Karcz
authors.forename: L
authors.initials: L
authors.lastname: Małecka
authors.forename: W
authors.initials: W
authors.lastname: Rydlewska-Sadowska
mesh_terms: D006328:Cardiac Catheterization; D002312:Cardiomyopathy, Hypertrophic / Q000503:physiopathology / Q000628:therapy*; D004452:Echocardiography; D015716:Electrocardiography, Ambulatory; D000431:Ethanol / Q000627:therapeutic use; D005080:Exercise Test; D017079:Exercise Tolerance; D005260:Female; D005500:Follow-Up Studies; D006346:Heart Septum; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014694:Ventricular Outflow Obstruction / Q000503:physiopathology*
chemical_list: D000431:Ethanol